1. van Deutekom A.W., Lewandowski A.J. Physical activity modification in youth with congenital heart disease: a comprehensive narrative review. Pediatr Res. 2020;89(7):1650–8. https://doi.org/10.1038/s41390-020-01194-8.
2. Lim T.B., Foo S.Y.R., Chen C.K. The role of epigenetics in congenital heart disease. Genes (Basel). 2021;12(3):390. https://doi.org/10.3390/genes12030390.
3. Reddy D.P., Viswamitra S. Cardiac embryology. In: CT and MRI in ongenital heart diseases. Springer, 2021. 29–54. https://doi.org/10.1007/978-981-15-6755-1_2.
4. Salman H.E., Alser M., Shekhar A. et al. Effect of left atrial ligation-driven altered inflow hemodynamics on embryonic heart development: Clues for prenatal progression of hypoplastic left heart syndrome. Biomech Model Mechanobiol. 2021;20(2):733–50. https://doi.org/10.1007/s10237-020-01413-5.
5. Burton G.J., Jauniaux E. Development of the human placenta and fetal heart: synergic or independent? Front Physiol. 2018;9:373. https://doi.org/10.3389/fphys.2018.00373.
6. Neufeld G., Cohen T., Gengrinovitch S., Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999;13(1):9–22.
7. Fowden A., Forhead A., Coan P., Burton G. The placenta and intrauterine programming. J Neuroendocrinol. 2008;20(4):439–50. https://doi.org/10.1111/j.1365-2826.2008.01663.x.
8. Saleemuddin A., Tantbirojn P., Sirois K. et al. Obstetric and perinatal complications in placentas with fetal thrombotic vasculopathy. Pediatr Dev Pathol. 2010;13(6):459–64. https://doi.org/10.2350/10-01- 0774-OA.1.
9. Verburg B.O., Jaddoe V., Wladimiroff J.W. et al. Fetal hemodynamic adaptive changes related to intrauterine growth: the Generation R Study. Circulation. 2008;117(5):649–59. https://doi.org/10.1161/CIRCULATIONAHA.107.709717.
10. Matthiesen N.B., Henriksen T.B., Agergaard P. et al. Congenital heart defects and indices of placental and fetal growth in a nationwide study of 924 422 liveborn infants. Circulation. 2016;134(20):1546–56. https://doi.org/10.1161/CIRCULATIONAHA.116.021793.
11. Khong T.Y., Mooney E.E., Ariel I. et al. Sampling and definitions of placental lesions: Amsterdam placental workshop group consensus statement. Arch Pathol Lab Med. 2016;140(7):698–713. https://doi.org/10.5858/arpa.2015-0225-CC.
12. Rychik J., Goff D., McKay E. et al. Characterization of the placenta in the newborn with congenital heart disease: distinctions based on type of cardiac malformation. Pediatr Cardiol. 2018;39(6):1165–71. https://doi.org/10.1007/s00246-018-1876-x.
13. Johnson J.A., Canavan T. Placental expression of vascular endothelial growth factor in patients with hypoplastic left heart syndrome. J Am Coll Cardiol. 2020;75(11 Suppl 1):630. https://doi.org/10.1016/s0735-1097(20)31257-2.
14. Barker D.J., Godfrey K.M., Gluckman P.D. et al. Fetal nutrition and cardiovascular disease in adult life. Lancet. 1993;341(8850):938–41. https://doi.org/10.1016/0140-6736(93)91224-a.
15. Menendez-Castro C., Rascher W., Hartner A. Intrauterine growth restriction-impact on cardiovascular diseases later in life. Mol Cell Pediatr. 2018;5(1):4. https://doi.org/10.1186/s40348-018-0082-5.
16. Zhao F., Lei F., Yan X. et al. Protective effects of hydrogen sulfide against cigarette smoke exposure-induced placental oxidative damage by alleviating redox imbalance via Nrf2 pathway in rats. Cell Physiol Biochem. 2018;48(5):1815–28. https://doi.org 10.1159/000492504.
17. Lu L., Kingdom J., Burton G.J., Cindrova-Davies T. Placental stem villus arterial remodeling associated with reduced hydrogen sulfide synthesis contributes to human fetal growth restriction. Am J Pathol. 2017;187(4):908–20. https://doi.org/10.1016/j.ajpath.2016.12.002.
18. Shen Y., Shen Z., Luo S. et al. The cardioprotective effects of hydrogen sulfide in heart diseases: from molecular mechanisms to therapeutic potential. Oxid Med Cell Longev. 2015;2015:925167. https://doi.org/10.1155/2015/925167.
19. Russell M.W., Moldenhauer J.S., Rychik J. et al. Damaging variants in proangiogenic genes impair growth in fetuses with cardiac defects. J Pediatr. 2019;213:103–9. https://doi.org/10.1016/j.jpeds.2019.05.013.
20. Laakkonen J.P., Lähteenvuo J., Jauhiainen S. et al. Beyond endothelial cells: vascular endothelial growth factors in heart, vascular anomalies and placenta. Vascul Pharmacol. 2019;112:91–101. https://doi.org/10.1016/j.vph.2018.10.005.
21. Llurba E., Sanchez O., Ferrer Q. et al. Maternal and foetal angiogenic imbalance in congenital heart defects. Eur Heart J. 2014;35(11):701–7. https://doi.org/10.1093/eurheartj/eht389.
22. Brodwall K., Leirgul E., Greve G. et al. Possible common aetiology behind maternal preeclampsia and congenital heart defects in the child: a cardiovascular diseases in Norway project study. Paediatr Perinat Epidemiol. 2016;30(1):76–85. https://doi.org/10.1111/ppe.12252.
23. Hertig A., Berkane N., Lefevre G. et al. Maternal serum sFlt1 concentration is an early and reliable predictive marker of preeclampsia. Clin Chem. 2004;50(9):1702–3. https://doi.org/10.1373/clinchem.2004.036715.
24. Cahill L.S., Stortz G., Chandran A.R. et al. Wave reflections in the umbilical artery measured by Doppler ultrasound as a novel predictor of placental pathology. EBioMedicine. 2021;67:103326. https://doi.org/10.1016/j.ebiom.2021.103326.
25. Yagel S., Cohen S.M., Goldman-Wohl D. An integrated model of preeclampsia: a multifaceted syndrome of the maternal cardiovascularplacental-fetal array. Am J Obstet Gynecol. 2021 Mar 9;S0002- 9378(20)31197-2. https://doi.org/10.1016/j.ajog.2020.10.023. [Online ahead of print].
26. Hanna J., Goldman-Wohl D., Hamani Y. et al. Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nat Med. 2006;12(9):1065–74. https://doi.org/10.1038/nm1452.
27. Tayade C., Hilchie D., He H. et al. Genetic deletion of placenta growth factor in mice alters uterine NK cells. J Immunol. 2007;178(7):4267–75. https://doi.org/10.4049/jimmunol.178.7.4267.
28. Yagel S. The developmental role of natural killer cells at the fetal-maternal interface. Am J Obstet Gynecol. 2009;201(4):344–50. https://doi.org/10.1016/j.ajog.2009.02.030.
29. Hanna J., Wald O., Goldman-Wohl D. et al. CXCL12 expression by invasive trophoblasts induces the specific migration of CD16- human natural killer cells. Blood. 2003;102(5):1569–77. https://doi.org/10.1182/blood-2003-02-0517.
30. Gamliel M., Goldman-Wohl D., Isaacson B. et al. Trained memory of human uterine NK cells enhances their function in subsequent pregnancies. Immunity. 2018;48(5):951–62.e5. https://doi.org/10.1016/j.immuni.2018.03.030.
31. Goldman-Wohl D., Gamliel M., Mandelboim O., Yagel S. Learning from experience: cellular and molecular bases for improved outcome in subsequent pregnancies. Am J Obstet Gynecol. 2019;221(3):183–93. https://doi.org/10.1016/j.ajog.2019.02.037.
